AI Article Synopsis

  • The treatment approach for glioblastoma (GBM) involves surgery followed by chemotherapy and radiotherapy, with the best outcomes linked to maximal tumor resection. A specialized neuro-oncology care center (NOC) employs advanced techniques to enhance patient outcomes through improved surgical methods.
  • In a study of 149 newly diagnosed GBM patients, those treated after the establishment of the NOC showed a significantly higher rate of complete tumor resection compared to those treated beforehand.
  • Patients achieving complete resection experienced better progression-free survival (PFS) and overall survival (OS), with no increase in neurological deficits post-surgery, indicating that the advanced surgical techniques used in the NOC are effective.

Article Abstract

Unlabelled: Treatment of glioblastoma (GBM) consists of microsurgical resection followed by concomitant radiochemotherapy and adjuvant chemotherapy. The best outcome regarding progression free (PFS) and overall survival (OS) is achieved by maximal resection. The foundation of a specialized neuro-oncology care center (NOC) has enabled the implementation of a large technical portfolio including functional imaging, awake craniotomy, PET scanning, fluorescence-guided resection, and integrated postsurgical therapy. This study analyzed whether the technically improved neurosurgical treatment structure yields a higher rate of complete resection, thus ultimately improving patient outcome.

Patients And Methods: The study included 149 patients treated surgically for newly diagnosed GBM. The neurological performance score (NPS) and the Karnofsky performance score (KPS) were measured before and after resection. The extent of resection (EOR) was volumetrically quantified. Patients were stratified into two subcohorts: treated before (A) and after (B) the foundation of the Regensburg NOC. The EOR and the PFS and OS were evaluated.

Results: Prognostic factors for PFS and OS were age, preoperative KPS, O⁶-methylguanine-DNA-methyltransferase () promoter methylation status, isocitrate dehydrogenase 1 () mutation status and EOR. Patients with volumetrically defined complete resection had significantly better PFS (9.4 vs. 7.8 months; = 0.042) and OS (18.4 vs. 14.5 months; = 0.005) than patients with incomplete resection. The frequency of transient or permanent postoperative neurological deficits was not higher after complete resection in both subcohorts. The frequency of complete resection was significantly higher in subcohort B than in subcohort A (68.2% vs. 34.8%; = 0.007). Accordingly, subcohort B showed significantly longer PFS (8.6 vs. 7.5 months; = 0.010) and OS (18.7 vs. 12.4 months; = 0.001). Multivariate Cox regression analysis showed complete resection, age, preoperative KPS, and promoter status as independent prognostic factors for PFS and OS. Our data show a higher frequency of complete resection in patients with GBM after the establishment of a series of technical developments that resulted in significantly better PFS and OS without increasing surgery-related morbidity.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5789336PMC
http://dx.doi.org/10.3390/brainsci8010005DOI Listing

Publication Analysis

Top Keywords

complete resection
24
resection
12
extent resection
8
newly diagnosed
8
specialized neuro-oncology
8
neuro-oncology care
8
care center
8
performance score
8
prognostic factors
8
factors pfs
8

Similar Publications

Background: The use of local consolidative therapy (LCT) in patients with oligometastatic non-small cell lung cancer (NSCLC) is rapidly evolving, with a preponderance of data supporting the benefits of such therapeutic approaches incorporating pulmonary resection for appropriately selected candidates. However, practices vary widely institutionally and regionally, and evidence-based guidelines are lacking.

Methods: The Society of Thoracic Surgeons assembled a panel of thoracic surgical oncologists to evaluate and synthesize the available evidence regarding the role of pulmonary resection as LCT.

View Article and Find Full Text PDF

Mediastinal mass syndrome represents a major threat to respiratory and cardiovascular integrity, with difficult evidence-based risk stratification for interdisciplinary management. We conducted a narrative review concerning risk stratification and difficult airway management of patients presenting with a large mediastinal mass. This is supplemented by a case report illustrating our individual approach for a patient presenting with a subtotal tracheal stenosis due to a large cyst of the thyroid gland.

View Article and Find Full Text PDF

Preoperative Vascular and Cranial Nerve Imaging in Skull Base Tumors.

Cancers (Basel)

December 2024

Department of Neurosurgery, Institute of Medicine, University of Tsukuba, Tsukuba 305-8575, Japan.

Skull base tumors such as meningiomas and schwannomas are often pathologically benign. However, surgery for these tumors poses significant challenges because of their proximity to critical structures such as the brainstem, cerebral arteries, veins, and cranial nerves. These structures are compressed or encased by the tumor as they grow, increasing the risk of unintended injury to these structures, which can potentially lead to severe neurological deficits.

View Article and Find Full Text PDF

[Efficacy and learning curve of 69 cases of robot-assisted resection of retroperitoneal benign tumors].

Zhonghua Wai Ke Za Zhi

January 2025

Department of Hepatobiliary and Pancreatic Surgery & Retroperitoneal Tumor Surgery, Affiliated Hospital of Qingdao University, Qingdao266001, China.

To explore the efficacy of robotic-assisted retroperitoneal benign tumor resection and to analyze its learning curve. This is a retrospective case series study. The data of patients who underwent robotic-assisted retroperitoneal benign tumor resection from August 2015 to February 2023 at the Department of Retroperitoneal Tumor Surgery was analyzed retrospectively.

View Article and Find Full Text PDF

Objective: Primary salivary gland squamous cell carcinoma (SCC) is extremely rare, accounting for 0.3-10.4 % of all salivary gland malignancies.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!